(NASDAQ: LENZ) Lenz Therapeutics's forecast annual revenue growth rate of 193.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 107.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Lenz Therapeutics's revenue in 2025 is $5,000,000.On average, 10 Wall Street analysts forecast LENZ's revenue for 2025 to be $375,037,040, with the lowest LENZ revenue forecast at $167,709,924, and the highest LENZ revenue forecast at $479,171,213. On average, 10 Wall Street analysts forecast LENZ's revenue for 2026 to be $1,446,954,452, with the lowest LENZ revenue forecast at $1,150,781,007, and the highest LENZ revenue forecast at $1,805,277,544.
In 2027, LENZ is forecast to generate $3,845,348,983 in revenue, with the lowest revenue forecast at $3,267,776,539 and the highest revenue forecast at $4,412,368,251.